Fizazi, K
Vukovic R, Kumburovic I, Joksimovic Jovic J, Jovicic N, Katanic Stankovic JS, Mihailovic V, et al
Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges
The GLP- 1 agonist (medication) works by mimicking the hormone
PGs Targets In some reports, the key function of PGs is shown in physiological immune responses and pathological conditions related to inflammation and tissue damage
[DOI] [PubMed] [Google Scholar] 13.A novel and compact review on the role of oxidative stress in female reproduction